MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    Cohort study and Review on Physiotherapy in the Rehabilitation and Pro-longed Bed Rest of Atypical Parkinsonism’s Syndrome Patients

    A. Mimpriss, J. Donnelly, L. Massey, B. Ghosh (Plymouth, United Kingdom)

    Objective: To present a cohort report on the physical decline and impact on activities of daily life (ADL) of prolonged bedrest for Atypical Parkinsonism's syndrome…
  • 2024 International Congress

    Prevalence of non-motor symptoms and their impact in quality of life in PD: a Mexican Registry, 2011-2019 (the ReMePark-2 study).

    A. Cervantes Arriaga, AJ. Hernandez Medrano, A. Dominguez Garcia, DP. Romero Terán, MF. Medina Perez, M. Rodriguez Violante, A. Abundes Corona, R. Solis Vivanco, AL. Guerra-Anzaldo, G. Rivera-Monroy, CF. álvarez-Hernández, RJ. Baños-Betancourt, WF. Moguel Cardín ()

    Objective: To determine the prevalence of non-motor symptoms (NMS) and their impact on quality of life (QoL) in Mexican individuals with Parkinson's disease (PD), aiming…
  • 2024 International Congress

    Transforming Parkinson’s Care in Africa: Establishing the First Ever Support Group for People With Parkinson’s Disease and Their Caregivers in Tanzania.

    M. Shayo, K. Haukila, T. Park, R. Walker, N. Fothergill-Misbah (Moshi, United Republic of Tanzania)

    Objective: To establish a support group for people with Parkinson's disease (PwP) and caregivers in Tanzania as part of the Transforming Parkinson’s Care in Africa…
  • 2024 International Congress

    WATCH-PD Qualitative Study: A Mental Model of Coping with Disease Progression

    A. Lerner, J. Mammen, R. Al-Rubayie, M. Kostrzebski, J. Adams (Rochester, USA)

    Objective: To qualitatively evaluate how individuals’ adjust to and cope with symptoms of Parkinson’s disease (PD). Background: The WATCH-PD qualitative study is evaluating meaningful symptoms…
  • 2024 International Congress

    Sympathetic Nervous System Overactivity in the Pre-Motor Stage of Parkinson’s Disease: Therapeutic Implications

    M. Tagliati, M. Gregorio, H. Maghzi, G. Obialisi, E. Hogg, C. Malatt, E. Tan, M. Kelly, H. Pomeroy, R. Artal, M. Shehata, B. Renner, Z. Fan, P. Sati, G. Pagano (Los Angeles, USA)

    Objective: To investigate sympathetic nervous system (SNS) activity in idiopathic REM behavior disorder (iRBD) subjects at risk for Parkinson's disease (PD), and the effect of…
  • 2024 International Congress

    Analysis of Patellar Reflex in Parkinson Disease Patients after an Acupuncture Treatment Protocol – Case Series Study

    CRP. Pereira (Porto, Portugal)

    Objective: To analyze the behavior of patellar reflexes in four Parkinson's Disease patients undergoing an acupuncture treatment protocol. Background: The investigation of rigidity physiology in…
  • 2024 International Congress

    Opicapone Effect on Sleep Disorders in Fluctuating Parkinson’s Disease Patients: Findings from the OASIS Trial

    J. Ferreira, M. Gago, R. Costa, M. Fonesca, J. Almeida, J. Rocha, J. Holenz, C. Trenkwalder (Lisbon, Portugal)

    Objective: The OASIS exploratory trial aimed to evaluate the effects of opicapone (OPC) on sleep disorders in Parkinson’s disease (PD) patients with motor fluctuations (MF)…
  • 2024 International Congress

    Efficacy of Opicapone and Levodopa with Different Levodopa Daily Doses in Parkinson’s Disease Patients with Early Motor Fluctuations: Findings from the Korean ADOPTION Study

    J. Lee, J. Ferreira, H. Ma, J. Rocha, B. Jeon (Seoul, Republic of Korea)

    Objective: To evaluate the effect of opicapone (OPC) 50 mg versus an additional levodopa (L-DOPA) dose of 100 mg in patients with Parkinson’s disease (PD)…
  • 2024 International Congress

    Continuous Subcutaneous Apomorphine Infusion (CSAI) Improved Confidence When Engaging in Everyday Activities: Survey of InfusON Study Participants

    P. Agarwal, A. Formella, N. Crouse, A. Breiteneicher, M. Grall (Kirkland, USA)

    Objective: Evaluate participants' perceptions of their confidence when engaging in daily activities and interpersonal relationships while using CSAI therapy, relative to the period before CSAI…
  • 2024 International Congress

    Multicentric Randomized Control Trial of Buspirone in Levodopa-Induced Dyskinesias

    H. Salhi, D. Maltête, S. Thobois, G. Fenelon, F. Ory, L. Defevre, G. Mangone, G. Defer, AR. Marques, S. Frismand, S. Drapier, JP. Azulay, C. Geny, G. Dupont, A. Doe-de-Maindreville, C. Barberot, D. Devos, JC. Corvol, O. Rascol, E. Audureau, P. Remy (Creteil, France)

    Objective: To investigate the efficacy of buspirone on levodopa induced dyskinesias (LID) in Parkinson disease (PD) patients Background: LID could be partially mediated by the…
  • « Previous Page
  • 1
  • …
  • 164
  • 165
  • 166
  • 167
  • 168
  • …
  • 181
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Welcome to the MDS Abstracts Site
    • Effect of marijuana on Essential Tremor: A case report
    • Advanced Search
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley